Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Calcaratarin D attenuates house dust mite-induced allergic asthma Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Sublingual monomeric allergoid immunotherapy improves airway inflammation, airway hyperresponsiveness and clinical symptoms in allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006
Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021
Correlation between nasal eosinophilic inflammation and bronchial reactivity to methacholine in allergic children sensitized to house dust mites (HDM) Source: Eur Respir J 2002; 20: Suppl. 38, 172s Year: 2002
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Evaluation of six-year allergen immunotherapy in allergic rhinitis and allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006
Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006
Comparison of late allergic inflammatory responses in asthma and rhinitis after nasal and bronchial allergen challenge Source: Eur Respir J 2001; 18: Suppl. 33, 269s Year: 2001
Sensitisation to house dust mite: its association with bronchial hyperresponsiveness and lung function in asthmatic children Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009
Humoral markers of inflammation in induced sputum of patients with bronchial asthma and allergic rhinitis in relation to exposure to pollen allergens Source: Eur Respir J 2004; 24: Suppl. 48, 595s Year: 2004
The effect of BCG treatment on the remodelling in the house dust mite induced allergic asthma in mice Source: Eur Respir J 2005; 26: Suppl. 49, 580s Year: 2005
Effect of nasal allergen challenge on non-invasive markers of inflammation in allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 592s Year: 2006
Potential reduction of bronchial hyperreactivity under allergic rhinitis Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
Small airways dysfunction: the link between allergic rhinitis and allergic asthma Source: Eur Respir J, 51 (2) 1701749; 10.1183/13993003.01749-2017 Year: 2018
Circulating platelets activity in patients sensitised to house dust mite suffering from persistent allergic rhinitis with or without asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 590s Year: 2005
Lower airway inflammation and hyperresponsiveness in allergic and non-allergic rhinitis Source: Annual Congress 2011 - Asthma: risk factors and comorbidities Year: 2011